Literature DB >> 22210181

Inflammation and immune surveillance in cancer.

Melvyn T Chow1, Andreas Möller, Mark J Smyth.   

Abstract

Chronic inflammation is a risk factor for tumor development. However, understanding the effect of the immune system on tumor development has only been significantly advanced over the past two decades. We now appreciate that the immune system, in addition to tumor-suppressive function by eliminating nascent transformed tumor cells, can also exert selection pressure on tumor cells and facilitate tumor growth by providing a favorable tumor microenvironment. Yet, the distinctions between tumor-promoting inflammation and tumor-suppressive immunity are still not clear due to the dual role of some cytokines and other molecules in the immune system. The danger signal hypothesis has shaped our view of the role of immunity in cancer development, but still little is known about the exact role of danger signal receptors in cancer progression. In this review, we introduce the processes of cancer immunoediting and inflammation-induced cancer and discuss what is currently known about the role of danger signal receptors in cancer development and progression. Copyright Â
© 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22210181     DOI: 10.1016/j.semcancer.2011.12.004

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  75 in total

1.  Treatments for hematologic malignancies in contrast to those for solid cancers are associated with reduced red cell alloimmunization.

Authors:  Dorothea Evers; Jaap Jan Zwaginga; Janneke Tijmensen; Rutger A Middelburg; Masja de Haas; Karen M K de Vooght; Daan van de Kerkhof; Otto Visser; Nathalie C V Péquériaux; Francisca Hudig; Johanna G van der Bom
Journal:  Haematologica       Date:  2016-09-15       Impact factor: 9.941

2.  Two immune-enhanced molecular subtypes differ in inflammation, checkpoint signaling and outcome of advanced head and neck squamous cell carcinoma.

Authors:  Bangrong Cao; Qifeng Wang; Huan Zhang; Guiquan Zhu; Jinyi Lang
Journal:  Oncoimmunology       Date:  2017-11-06       Impact factor: 8.110

Review 3.  Metabolism and its sequelae in cancer evolution and therapy.

Authors:  Robert J Gillies; Robert A Gatenby
Journal:  Cancer J       Date:  2015 Mar-Apr       Impact factor: 3.360

4.  Quantitative patterns of Hsps in tubular adenoma compared with normal and tumor tissues reveal the value of Hsp10 and Hsp60 in early diagnosis of large bowel cancer.

Authors:  Francesca Rappa; Alessandro Pitruzzella; Antonella Marino Gammazza; Rosario Barone; Emanuele Mocciaro; Giovanni Tomasello; Francesco Carini; Felicia Farina; Giovanni Zummo; Everly Conway de Macario; Alberto Jl Macario; Francesco Cappello
Journal:  Cell Stress Chaperones       Date:  2016-08-04       Impact factor: 3.667

5.  Cancer risk in cutaneous lupus erythematosus: a population-based cohort study.

Authors:  Abha G Singh; Cynthia S Crowson; Siddharth Singh; Mark Denis P Davis; Hilal Maradit-Kremers; Eric L Matteson; Vaidehi R Chowdhary
Journal:  Rheumatology (Oxford)       Date:  2016-08-12       Impact factor: 7.580

6.  Loss of Interleukin-17RA Expression is Associated with Tumour Progression in Colorectal Carcinoma.

Authors:  Boon Yean Chai; Wai Kien Yip; Noraini Dusa; Norhafizah Mohtarrudin; Heng Fong Seow
Journal:  Pathol Oncol Res       Date:  2020-05-27       Impact factor: 3.201

7.  Allergies and the Subsequent Risk of Cancer among Elderly Adults in the United States.

Authors:  Monica D'Arcy; Donna R Rivera; Andrew Grothen; Eric A Engels
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-01-30       Impact factor: 4.254

8.  The Role of Childhood Infections and Immunizations on Childhood Rhabdomyosarcoma: A Report From the Children's Oncology Group.

Authors:  Hari Sankaran; Heather E Danysh; Michael E Scheurer; M Fatih Okcu; Stephen X Skapek; Douglas S Hawkins; Logan G Spector; Erik B Erhardt; Seymour Grufferman; Philip J Lupo
Journal:  Pediatr Blood Cancer       Date:  2016-05-19       Impact factor: 3.167

Review 9.  Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer.

Authors:  Kazuhiko Shien; Vassiliki A Papadimitrakopoulou; Ignacio I Wistuba
Journal:  Lung Cancer       Date:  2016-06-21       Impact factor: 5.705

Review 10.  Complex role of γδ T-cell-derived cytokines and growth factors in cancer.

Authors:  Andrew G Ramstead; Mark A Jutila
Journal:  J Interferon Cytokine Res       Date:  2012-10-18       Impact factor: 2.607

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.